Morepen Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +81.1% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
ML

Morepen Laboratories Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Morepen Laboratories Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹484Cr
+6.8% YoY
+17.5% QoQ
Net profit
₹28Cr
+3.7% YoY
−31.7% QoQ
Margin
10%
+2 pp YoY
+3 pp QoQ

Based on Morepen Laboratories Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹117
Market cap₹6.6K Cr
P/E56.4

The short version

Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23). Quarterly EBITDA (Consolidated) Q3 FY26: Rs. 50 crores, up 42% YoY (Page 23).

From Morepen Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23).
  • Q3 FY26 standalone gross revenue: Rs. 462 crores, up 23% from Q3 FY25 Rs. 374 crores (Page 22).
  • Medical Devices revenue Q3 FY26: Rs. 78 crores vs Rs. 73 crores in Q3 FY25, 6% growth (Page 19).
  • BP Monitor revenue and other medical devices segments increased significantly, e.g., BP monitors 17.4% share (Page 20).

2 more points from Morepen Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Morepen Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Morepen Laboratories Ltd Q3 FY26 results — key figures

Morepen Laboratories Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue484453+6.8%412+17.5%
Operating profit (EBITDA)4636+27.8%31+48.4%
Operating margin10%8%+2 pp7%+3 pp
Profit before tax35350%46-23.9%
Net profit (PAT)2827+3.7%41-31.7%
EPS (₹)0.500.49+2%0.75-33.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Morepen Laboratories Ltd Q3 FY26 results?

Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23). Quarterly EBITDA (Consolidated) Q3 FY26: Rs. 50 crores, up 42% YoY (Page 23).

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.